

## EANM Focus 1, the international conference on Molecular Imaging and Theranostic in Prostate Cancer

1-3 February 2018

Valencia, Spain

### Definitions

- For all questions, unless stated otherwise, it is assumed that all treatments and diagnostic procedures mentioned are readily available, there are no treatment and/or imaging contraindications. This premise does not apply when in the answers mention the availability of imaging methods. Questions refer to non-frail patients and for patients with prostate adenocarcinoma (if not stated otherwise).

### The following definitions/abbreviations are used:

- **BS:** Bone Scintigraphy (whole body planar scintigraphy with  $^{99m}\text{Tc}$ -Diphosphonates)
- **CT:** Computed Tomography (whole body CT (chest, abdomen and pelvis) with contrast media if necessary)
- **NaF PET:** Fluoride PET/CT (whole body PET/CT with  $^{18}\text{F}$ -NaF)
- **Whole Body MRI:** MRI with morphologic and diffusion sequences
- **mpMRI:** MRI with morphologic, diffusion and contrast enhanced sequences directed towards the true pelvis, prostate gland or prostatectomy bed
- **Choline PET:** whole body PET/CT with  $^{18}\text{F}$ - or  $^{11}\text{C}$ - Choline
- **PSMA PET:** whole body PET/CT with  $^{68}\text{Ga}$ -PSMA
- **FC PET:** whole body PET/CT with  $^{18}\text{F}$ -Fluciclovine
- **Prostate Cancer targeted PET:** PET/CT with either Choline, PSMA or Fluciclovine
- **Conventional Imaging Modalities:** BS and/or CT
- **Modern Imaging Modalities:** MRI (wb and/or mp) and/or PET (Choline, PSMA or FC)
- **CNPC:** castrate naïve prostate cancer
- **CRPC:** castrate resistant prostate cancer
- **mCRPC:** metastatic castrate resistant prostate cancer
- **Advanced PC:** prostate cancer either locally advanced or metastatic
- **Radiopharmaceutical:** a pharmaceutical compound with a radioisotope
- **Therapeutic Radiopharmaceutical:** a radiopharmaceutical with direct therapeutic effect (such as  $^{223}\text{Radium}$  or  $^{177}\text{LutetiumPSMA}$ )
- **Intermediate risk patients at presentation:** PSA 10-20 ng/ml or cT2c or Gleason 7
- **High risk patients at presentation:** Any of the following: PSA > 20 ng/ml; Gleason  $\geq 8$ ; cT  $\geq 3$ ; N1
- **Symptomatic patients:** Requiring any regular pain medication for prostate cancer related pain
- **Biochemical recurrence (BCR)** rising serum PSA after definitive initial therapy